NASD · Healthcare · Drug Manufacturers - Specialty & Generic · Israel
Kamada Ltd is a small cap company (market value between $300 million and $2 billion) in the Drug Manufacturers - Specialty & Generic industry.
Intrinsic value, DCF valuation, financial health and value investing analysis for the Kamada Ltd stock.
Undervalued: intrinsic value $11.36 per share, market price $7.70, margin of safety 32.2% (as of 2026-10-30).
Discounting its cash flows at 9.6% (average of 3 methods) values the shares at $11.36; the price of $7.70 is 32% below that value, and 75% of that value comes from beyond year five.
Leak Score: 64/100 on 12 of 12 signals (Faint Leak).
All 84 Drug Manufacturers - Specialty & Generic stocks
3 more in this industry show a wider margin of safety.
KMDA is undervalued (as of the 2026-10-30 close). Discounting its cash flows at 9.6% (average of 3 methods) values the shares at $11.36; the price of $7.70 is 32% below that value, and 75% of that value comes from beyond year five.
$11.36 per share (as of the 2026-10-30 close), against a market price of $7.70. That is a margin of safety of 32.2%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
64 out of 100, which we rate "Faint Leak", on 12 of 12 value investing signals.